Last reviewed · How we verify
NCT05174117
Influence of Different Light Dose on the Adverse Effect of Swallowing for Esophageal Carcinoma
NA trial testing single irradiation in Esophagus Cancer in 57 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | The First Affiliated Hospital of Henan University of Science and Technology |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 57 |
| Start date | 1 January 2022 |
| Primary completion | 31 December 2022 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- single irradiation
- Double irradiation
Conditions studied
- Esophagus Cancer — all drugs for Esophagus Cancer →
Sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Who can join
Adults 18 to 80, any sex, with Esophagus Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this experiment is to study the alleviating effects and side effects of different laser irradiation doses on esophageal stricture of esophageal cancer in order to find the appropriate dose of light.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05174117
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Esophagus Cancer
Currently open trials in the same condition.
- NCT07070466 — Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA · Phase 2 · recruiting
- NCT07063901 — Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer · recruiting
- NCT06550063 — HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes · recruiting
- NCT06385717 — Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer · recruiting
- NCT06430658 — Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer · Phase 2 · recruiting
Other The First Affiliated Hospital of Henan University of Science and Technology trials
Trials by the same sponsor.
- NCT07533305 — Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic · Phase 2 · not yet recruiting
- NCT07347080 — A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) · EARLY_PHASE1 · recruiting
- NCT06418945 — Clinical Study on the Effect of Removal of Porphyromonas Gingivalis on Prognosis of Esophageal Cancer After Radical Surg · Phase 3 · not yet recruiting
- NCT06464614 — Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. · Phase 2 · not yet recruiting
- NCT06722300 — Clinical Study on the Impact of Eradication of Oral Porphyromonas Gingivalis on the Prognosis of Early Esophageal Cancer · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05174117 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Henan University of Science and Technology
- Last refreshed: 30 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05174117.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing